Amplitude Vascular Systems Partners with Jacobs Institute to Expedite Clinical Trials for Coronary and Carotid Indications
Amplitude Vascular Systems (AVS), a medical device company focused on innovative solutions for cardiovascular disease, has announced a strategic partnership with the Jacobs Institute, a non-profit medical device innovation center in Buffalo, New York. This collaboration aims to accelerate the clinical evaluation and potential market launch of AVS's groundbreaking PULSE IVL System for treating both coronary and carotid lesions.
The PULSE IVL System represents a significant advancement in intravascular lithotripsy (IVL), a minimally invasive procedure used to treat calcified lesions in blood vessels. The system utilizes a novel hydraulics technology to fracture calcified lesions and expand the diseased vessel with a single device, providing a more efficient and less invasive treatment option for patients suffering from these conditions.
A Game Changer in IVL Technology
The PULSE IVL System is a departure from traditional IVL approaches, which often require multiple devices and procedures. AVS Executive Chairman Mark Toland highlights the system's key differentiators in a recent podcast with Bloomberg Intelligence: "The PULSE IVL System is differentiated from the current technology in the market to make it more flexible and durable." This enhanced flexibility and durability make the system more adaptable to a wider range of patient needs, potentially leading to better outcomes.
Clinical Trials and Market Expansion
The partnership between AVS and the Jacobs Institute is designed to streamline the clinical trial process and expedite the regulatory approval of the PULSE IVL System for both coronary and carotid indications. The Jacobs Institute brings its extensive experience in clinical research and regulatory affairs, while AVS provides its innovative lithotripsy technology. This collaboration is expected to significantly reduce the time required to bring the PULSE IVL System to market, ultimately benefiting patients.
Expanding Treatment Options for Stroke Patients
The partnership between AVS and the Jacobs Institute is not only focused on expanding treatment options for coronary artery disease but also on improving stroke care. The PULSE IVL System's unique mechanism of action holds significant promise for treating carotid lesions, which are a leading cause of stroke. By addressing these lesions effectively, the system could potentially reduce the incidence of stroke and its associated morbidity and mortality.
"We believe the PULSE IVL System is the perfect fit for the structure we’ve built at the Jacobs Institute," said Dr. Adnan Siddiqui, a key figure at the Jacobs Institute. "By fostering an environment that nurtures innovation, the Jacobs Institute will help to bring this technology to patients sooner, ultimately providing better treatment options for patients with coronary and carotid artery diseases. We are especially excited about studying the PULSE IVL System in carotids to improve stroke care. We believe its unique mechanism of action may be an important solution for the diffuse and eccentric nature of many of our carotid disease patients."
A Promising Future for IVL
The partnership between AVS and the Jacobs Institute marks a significant step forward in the field of IVL. The PULSE IVL System's innovative technology, coupled with the expertise of the Jacobs Institute, has the potential to revolutionize the treatment of coronary and carotid lesions. This collaboration is expected to lead to improved treatment outcomes for patients and a significant impact on public health.
The Next Big Thing in IVL
The PULSE IVL System is poised to become a leading player in the growing IVL market. The aging global population is experiencing an increase in calcified lesions, driving demand for effective IVL treatment options. AVS's focus on innovation and its commitment to expanding the clinical applications of the PULSE IVL System position the company for significant growth in the years to come.
A Look Ahead
As the partnership between AVS and the Jacobs Institute progresses, the medical community will eagerly await the results of the clinical trials. If the trials are successful, the PULSE IVL System could become the standard of care for treating coronary and carotid lesions, significantly improving patient outcomes and reducing the burden of these debilitating conditions.
